FENNEC PHARMACEUTICALS INC.
FENC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for FENC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of PEDMARK, a treatment to reduce the risk of ototoxicity associated with cisplatin chemotherapy in pediatric patients. The company reported net income of $2.0M on revenue of $17.9M as of 2026-06-30 [sec].
Key risk: Single product dependency
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 catalyst · 1 FDA decision for FENNEC PHARMACEUTICALS INC..
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of PEDMARK, a treatment to reduce the risk of ototoxicity associated with cisplatin chemotherapy in pediatric patients. The company reported net income of $2.0M on revenue of $17.9M as of 2026-06-30 [sec].
- Fennec's sole marketed product is PEDMARK, approved for reducing the risk of ototoxicity in pediatric patients receiving cisplatin chemotherapy [sec_mda · as of 2026-08-13].
- As of 2026-06-30, the company reported cash & equivalents of $41.2M, total revenue of $17.9M, and net income of $2.0M [sec].
- The company continues to pursue various strategic alternatives including collaborations with other pharmaceutical and biotechnology companies [sec_mda · as of 2026-08-13].
- Net cash provided by operating activities was $2,429 (in thousands) for the six months ended June 30, 2026, compared to cash used of $(8,004) in the same period of 2025 [sec_mda · as of 2026-08-13].
- Working capital increased by $3,581 (in thousands) between June 30, 2026 and December 31, 2025, driven by higher cash balance [sec_mda · as of 2026-08-13].
What works
- Fennec has achieved positive net income of $2.0M as of 2026-06-30, indicating a shift toward profitability [sec].
- The company improved operating cash flow, with net cash provided by operating activities of $2,429 (in thousands) in the first half of 2026 versus a use of $(8,004) in the same period of 2025 [sec_mda · as of 2026-08-13].
- Cash and equivalents increased to $41.2M as of 2026-06-30, providing a solid liquidity position [sec].
- PEDMARK addresses a specific unmet medical need in pediatric oncology, with a clear regulatory approval and commercialization pathway [sec_mda · as of 2026-08-13].
What to weigh
- Fennec is heavily dependent on a single product, PEDMARK, making it vulnerable to market or regulatory changes affecting that product [sec_mda · as of 2026-08-13].
- The company's projections of further capital requirements are subject to substantial uncertainty, and working capital needs may fluctuate based on numerous factors [sec_mda · as of 2026-08-13].
- The company has a history of net losses in prior periods, with a net loss increase of $6,108 (in thousands) in the nine-month period ended September 30, 2025 compared to the same period in 2024 [sec_mda · as of 2025-11-13].
- PEDMARK's patent/exclusivity is set to expire on 2039-07-01, which could eventually expose the product to generic competition [catalyst_timeline].
From the filings
Quoted directly from source documents.
The company continues to pursue strategic alternatives including collaborations.
“We continue to pursue various strategic alternatives including collaborations with other pharmaceutical and biotechnology companies.”
SEC MD&A · August 13, 2026
Net cash provided by operating activities improved in the first half of 2026.
“Net cash provided by/(used in) operating activities | | $ | 2,429 | | $ | (8,004)”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2039-07-01 · Patent_Expiry · PEDMARK — Patent/Exclusivity Expiry: PEDMARK — The patent/exclusivity for PEDMARK is scheduled to expire, which could allow generic competition and impact revenue.
Risks & what to watch (4)›
Key risks
- Single product dependency — Fennec relies entirely on PEDMARK; any setback in sales, regulation, or competition could severely impact the company [sec_mda · as of 2026-08-13].
- Capital requirement uncertainty — Projections of further capital requirements are subject to substantial uncertainty, with working capital needs fluctuating based on many factors [sec_mda · as of 2026-08-13].
- Patent expiry risk — PEDMARK's patent/exclusivity expires on 2039-07-01, potentially opening the market to generic competition [catalyst_timeline].
- Historical net losses — The company experienced increased net losses in prior periods, e.g., a $6,108 thousand increase in the nine months ended September 30, 2025 vs. 2024 [sec_mda · as of 2025-11-13].
What to watch
- Monitor PEDMARK sales growth and market penetration, as revenue is the primary driver of financial performance [sec_mda · as of 2026-08-13].
- Track the company's progress in pursuing strategic alternatives, including potential collaborations or partnerships [sec_mda · as of 2026-08-13].
- Watch for updates on operating cash flow trends, especially whether the positive trend from H1 2026 continues [sec_mda · as of 2026-08-13].
- Observe any developments regarding PEDMARK's patent protection or potential generic entry as the 2039 expiry approaches [catalyst_timeline].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run FENNEC PHARMACEUTICALS INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available FENNEC PHARMACEUTICALS INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.78 · 5% dilution
Lead: Approved
1 candidate
1 upcoming, next in ~4688d
0 buys · 6 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
86
Total value held
$53.7M
| Holder | Shares | Value |
|---|---|---|
| southpoint capital advisors lp | 2,744,741 | $16.9M |
| vanguard capital management llc | 1,794,288 | $11.0M |
| blackrock, inc. | 1,368,176 | $8.4M |
| geode capital management, llc | 371,738 | $2.3M |
| state street corp | 359,055 | $2.2M |
| morgan stanley | 211,108 | $1.3M |
| vanguard portfolio management llc | 168,473 | $1.0M |
| citadel advisors llc | 153,610 | $945K |
| northern trust corp | 152,123 | $936K |
| lion point capital, lp | 112,434 | $691K |
Showing top 10 of 86 institutional holders of FENNEC PHARMACEUTICALS INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 3.6%
- Days to cover
- 3.7
- Shares short
- 930,606
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FENC short interestGovernance
Frequently asked questions
What is the AI investment thesis for FENNEC PHARMACEUTICALS INC.?
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of PEDMARK, a treatment to reduce the risk of ototoxicity associated with cisplatin chemotherapy in pediatric patients. The company reported net income of $2.0M on revenue of $17.9M as of 2026-06-30 [sec].
What is FENNEC PHARMACEUTICALS INC.'s lead drug candidate?
FENNEC PHARMACEUTICALS INC.'s most advanced tracked candidate is pedmark (Approved) for reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors.
What is FENNEC PHARMACEUTICALS INC.'s next catalyst?
FENNEC PHARMACEUTICALS INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: PEDMARK" — expected July 1, 2039.
Who is the CEO of FENNEC PHARMACEUTICALS INC.?
Mr. Jeffrey S. Hackman is the chief executive officer of FENNEC PHARMACEUTICALS INC. (FENC).
Where is FENNEC PHARMACEUTICALS INC. headquartered?
FENNEC PHARMACEUTICALS INC. (FENC) is headquartered in Research Triangle Park, NC, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.